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Abstract
Aims/hypothesis Endothelial glycocalyx perturbation con-
tributes to increased vascular permeability. In the present
study we set out to evaluate whether: (1) glycocalyx is
perturbed in individuals with type 2 diabetes mellitus, and (2)
oral glycocalyx precursor treatment improves glycocalyx
properties.
Methods Male participants with type 2 diabetes (n=10) and
controls (n=10) were evaluated before and after 2 months
of sulodexide administration (200 mg/day). The glycocalyx
dimension was estimated in two different vascular beds
using sidestream dark field imaging and combined fluores-
cein/indocyanine green angiography for sublingual and
retinal vessels, respectively. Transcapillary escape rate of
albumin (TERalb) and hyaluronan catabolism were assessed
as measures of vascular permeability.
Results Both sublingual dimensions (0.64 [0.57–0.75] μm
vs 0.78 [0.71–0.85] μm, p<0.05, medians [interquartile
range]) and retinal glycocalyx dimensions (5.38 [4.88–
6.59] μm vs 8.89 [4.74–11.84] μm, p<0.05) were reduced
in the type 2 diabetes group compared with the controls
whereas TERalb was increased (5.6±2.3% vs 3.7±1.7% in
the controls, p<0.05). In line with these findings, markers
of hyaluronan catabolism were increased with diabetes
(hyaluronan 137±29 vs 81±8 ng/ml and hyaluronidase
78±4 vs 67±2 U/ml, both p<0.05). Sulodexide increased
both the sublingual and retinal glycocalyx dimensions in
participants with diabetes (to 0.93 [0.83–0.99] μma n dt o
5.88 [5.33–6.26] μm, respectively, p<0.05). In line, a
trend towards TERalb normalisation (to 4.0±2.3%) and
decreases in plasma hyaluronidase (to 72±2 U/ml, p<
0.05) were observed in the diabetes group.
Conclusion/interpretation Type 2 diabetes is associated
with glycocalyx perturbation and increased vascular per-
meability, which are partially restored following sulodexide
administration. Further studies are warranted to determine
whether long-term treatment with sulodexide has a benefi-
cial effect on cardiovascular risk.
Trial registration www.trialregister.nl NTR780/http://isrctn.
org ISRCTN82695186
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Introduction
Diabetes mellitus is characterised by an increased propen-
sity towards vascular complications. Microvascular com-
plications, such as retinopathy and nephropathy, as well as
macrovascular complications are largely responsible for
morbidity and mortality in type 2 diabetes mellitus patients
[1–3]. An early sign of vascular damage is increased
vascular permeability, which may eventually be associated
with microalbuminuria at a later stage. Although the
pathophysiology leading to increased vascular permeability
and microalbuminuria and the link with cardiovascular
complications have not been fully elucidated, hyperglycae-
mia is likely to be a causal factor [4].
The endothelial glycocalyx layer consisting of proteo-
glycans with their associated glycosaminoglycans (GAGs)
[5–9], covers the luminal side of each vessel wall. Under
physiological conditions, the glycocalyx shields the endo-
thelial lining from direct contact with circulating blood
elements [3]. Recently, we observed that acute hyper-
glycaemia resulted in a profound perturbation of the
endothelial glycocalyx, which coincided with vascular
dysfunction and activation of the coagulation system in
healthy volunteers [5]. In fact, with respect to chronic
hyperglycaemia, patients with type 1 diabetes mellitus were
characterised by a 50% decrease in glycocalyx volume.
Loss of glycocalyx volume closely correlated with in-
creased plasma hyaluronidase levels, indicative of enhanced
hyaluronan catabolism [10]. Glycocalyx perturbation has
been associated with a wide spectrum of vascular abnor-
malities in experimental models, including increased
vascular permeability as well as increased adhesion of
leucocytes and thrombocytes [11, 12]. In animal models,
restoration of the glycocalyx reversed these abnormalities
[11]. This led to the concept that reversal of glycocalyx
damage may be an attractive therapeutic target capable of
preserving vascular integrity. In vitro studies have sug-
gested that supplementation of glycocalyx constituents in
part restored glycocalyx damage through both increased N-
acetyl-glucosamine (GlcNAc)-driven GAG synthesis and
decreased GAG catabolism [13, 14]. Sulodexide is a
commercially available compound consisting of heparan
sulphate (80%) and dermatan sulphate (20%). Sulodexide is
degraded in the digestive tract into GlcNAc building
blocks, leading to an increase in the precursors available
for GAG synthesis [14, 15]. In vitro studies have shown
that sulodexide attenuates hyperglycaemia-associated endo-
thelial permeability in vitro through enhanced GAG
synthesis [16], but the effect of sulodexide treatment on
diabetes-associated microalbuminuria in vivo is less clear.
In the present study, we thus hypothesised that increasing
the precursors available for GAG synthesis could improve
endothelial glycocalyx properties in type 2 diabetes mellitus
patients. To this end, we evaluated the glycocalyx dimen-
sion in two different vascular beds before and after oral
administration of sulodexide for 8 weeks.
Methods
Study population In this investigator-initiated study, we
enrolled ten non-smoking men with diabetes mellitus type 2
without microalbuminuria (based on 24 h urine micro-
albuminuria measurement in the 6 months preceding the
study), retinopathy or macrovascular disease (defined as a
history of myocardial infarction, stroke, peripheral vascular
disease or signs of macrovascular disease at physical
examination). All patients used oral antihyperglycaemic
medication and patients using antihypertensive medication
were excluded from the study. Statins were discontinued at
least 4 weeks prior to study initiation. Ten normoglycaemic
non-smoking age-matched healthy men served as an age-
matched control group. Participants were asked to refrain
from heavy physical exercise 24 h prior to the study visit.
Alcohol, caffeine and metformin were withheld at least 12 h
before the study. All participants gave written informed
consent, and approval was obtained from the internal
review board of the Academic Medical Centre. The study
was registered in the Netherlands Trial Register (NTR780/
ISRCTN82695186). The study was carried out in accor-
dance with the principles of the Declaration of Helsinki.
Study design In patients and age-matched controls we
measured: (1) local sublingual glycocalyx thickness using
sidestream dark field (SDF) imaging; (2) retinal glycocalyx
thickness using fluorescein and indocyanine green angiog-
raphy (FAG/ICG); (3) transcapillary escape rate of albumin
(TERalb); and (4) circulating plasma levels of hyaluronan
and its degrading enzyme hyaluronidase both at baseline
and after 8 weeks of sulodexide administration (200 mg/
day; 25 mg/capsule, Alfa Wasserman, Milan, Italy).
Sulodexide is a glycosaminoglycan of natural origin
extracted from mammalian intestinal mucosa, containing a
mixture of 80% low-molecular-mass heparan sulphate and
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three times, from which the means of the last two
measurements were used as systolic and diastolic blood
pressure values.
Endothelial glycocalyx dimension We assessed the endo-
thelial glycocalyx dimension of both the sublingual and the
retinal circulations. The determination of the erythrocyte–
endothelium gap is the gold standard for glycocalyx
measurement in vivo [17] as the endothelial glycocalyx
allows limited access to erythrocytes. Using this principle,
the sublingual glycocalyx dimension was estimated using
SDF imaging [17]. Briefly, in each individual approximate-
ly 1,000 measurement sites of 10 μm in length were
marked in sublingual vessels. At each measurement site,
multiple estimates of the erythrocyte column width were
made by measuring both the median erythrocyte width as
well as the 90th percentile of erythrocyte width distribution.
For vessels with diameters ranging from 10 to 20 μm, a
functional estimate of glycocalyx dimension was estimated
by comparing the 50th percentile of erythrocyte width with
the 90th percentile of erythrocyte width (Fig. 1). Based on
these estimates, a single median value for glycocalyx
dimension was calculated for each individual. The repro-
ducibility of SDF measurements used to estimate glyco-
calyx dimension is good within our centre, with an
intersession coefficient of variation of 5.6±3.2% (n=10
controls measured on two separate occasions). The same
principle can be applied to retinal endothelial glycocalyx
measurement with fluorescence angiography. This method
uses the intravascular distribution of two different fluores-
cent tracers: fluorescein and indocyanine green [18].
Comparable with the exclusion of erythrocytes, the endo-
thelial glycocalyx also allows limited access to plasma
macromolecules, whereas smaller tracers can readily per-
meate into the glycocalyx [19]. In the retinal capillaries,
fluorescein fills up the entire vascular compartment while
indocyanine green binds to albumin and is therefore
excluded by the glycocalyx layer. By calculating the
difference between the two compartments, the dimension
of the glycocalyx layer in retinal vessels can be estimated.
Retinal glycocalyx dimensions, represented by the indoc-
yanine green exclusion zone on retinal angiography, were
determined in larger retinal vessels (diameter on FAG:
90 μm and above), thereby avoiding the heterogeneity of
glycocalyx dimensions in smaller vessels.
Transcapillary escape rate of albumin
Vascular permeability was determined by the transcapillary
escape rate of
125I-labelled albumin (TERalb)[ 20].
125I-
labelled albumin solution of 100 kBq in 5 ml saline was
infused as an intravenous bolus. Blood samples were drawn
from the contralateral arm at baseline, and at 5, 10, 15, 20,
30, 45 and 60 min. Plasma radioactivity was measured in
each sample and in a urine sample, collected at the end of
the procedure, using a scintillation detector (automatic γ-
counter). TERalb was expressed as the percentage decline in
plasma radioactivity from 10 to 60 min after injection.
Biochemical variables
Glucose was assessed using the hexokinase method (Gluco-
quant, Hitachi 917; Hitachi, Valbonne, France). HbA1c was
measured by HPLC (Reagens Bio-Rad Laboratories, Vee-
nendaal, the Netherlands) on a Variant II system (Bio-Rad
Laboratories, Hemel Hempstead, UK). Plasma C-reactive
protein (CRP) levels were measured with a commercially
available assay (Roche Diagnostics, Basel, Switzerland).
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Fig. 1 Measurement of sublingual glycocalyx dimension using SDF
imaging
2648 Diabetologia (2010) 53:2646–2655Total cholesterol, HDL-C, and triacylglycerols were mea-
sured by standard enzymatic methods (Roche Diagnostics).
LDL-C was calculated using the Friedewald formula.
Alanine aminotransferase and aspartate aminotransferase
were measured by pyridoxalphosphate activation assay
(Roche Diagnostics). Creatinine was measured by Jaffe
kinetic colorimetric test (Roche Diagnostics) on Modular
P800 (Roche Diagnostics). For further analysis, plasma
aliquots were snap-frozen and stored at −80°C. Quantitative
total plasma hyaluronan levels were measured by enzyme-
linked immunosorbent assay (Echelon Biosciences, Salt
Lake City, UT, USA) [21]. Plasma hyaluronidase levels
were determined with an assay as described previously by
Nieuwdorp et al. [10].
Statistical analysis
Results are expressed as means ± SD. Baseline differences
between controls and patients with type 2 diabetes were
tested using an unpaired Mann–Whitney test (two-tailed).
Differences within groups before and after treatment were
tested using a paired Student’s t test (two-tailed). CRP and
triacylglycerols were not normally distributed. Therefore,
we present medians (interquartile ranges) and used non-
parametric tests for these values. Analyses were performed
with SPSS version 11.5 (Chicago, IL, USA). A p value<
0.05 was defined as statistically significant.
Results
Clinical characteristics Clinical characteristics of the par-
ticipants are listed in Table 1. As compared with controls,
patients with type 2 diabetes were characterised by
increased glycaemic indices, diastolic blood pressure as
well as increased CRP levels. No significant changes in
BMI, HbA1c or glucose levels were observed with
sulodexide administration in patients and controls. Other
than an increased incidence of epistaxis in one healthy
volunteer, no side effects were reported.
Endothelial glycocalyx thickness measured with SDF
imaging and FAG/ICG Patients with type 2 diabetes
mellitus were characterised by reduced sublingual glyco-
calyx dimensions compared with the controls at baseline:
0.64 (0.57–0.75) μm (type 2 diabetes) vs 0.78 (0.71–0.85)
μm (controls; p<0.05 type 2 diabetes vs controls; Fig. 2).
Following sulodexide treatment the average sublingual
glycocalyx thickness increased in diabetic patients (to
0.93 [0.83–0.99] μm; p<0.05 placebo vs sulodexide;
Fig. 3). In controls, sulodexide had no significant effect
Table 1 Baseline characteristics of participants
Characteristic Participants with type 2 diabetes Controls
Baseline After 8 weeks
of sulodexide
p
a Baseline p
b After 8 weeks
of sulodexide
p
c
n=10 n=10 n=10 n=10
Age (years) 51.9±8.4 51.9±8.4 p=NS 56.3±8.5 p=NS 56.3±8.5 p=NS
Duration of diabetes (years) 5.1±5.6 5.1±5.6 p=NS
BMI (kg/m
2) 29.7±5.5 29.6±5.3 p=NS 27±2.1 p=NS 26.9±1.8 p=NS
SBP (mmHg) 141±14 139±18 p=NS 135±15 p=NS 141±27 p=NS
DBP (mmHg) 87±8 84±9 p=NS 82±8 p<0.05 81±6 p=NS
Glucose (mmol/l) 7.1±2.0 7.3±2.4 p=NS 4.9±0.4 p=0.002 5.2±0.6 p=NS
HbA1c (%) 7.1±1.2 7.1±1.2 p=NS 5.6±0.3 p<0.001 5.5±0.2 p=NS
TC (mmol/l) 5.6±1.0 5.3±1.4 p=NS 6.3±1.3 p=NS 5.5±0.9 p=NS
LDL-C (mmol/l) 3.4±0.8 3.1±1.3 p=NS 4.4±1.1 p=NS 3.5±1.0 p=NS
HDL-C (mmol/l) 1.1±0.3 1.0±0.3 p=NS 1.4±0.1 p=0.001 1.4±0.3 p=NS
TG (mmol/l) 2.0 (1.4–3.5) 2.1 (1.1–3.0) p=NS 1.0 (0.9–1.3) p=0.001 1.3 (0.8–1.4) p=NS
CRP (mg/l) 1.9 (0.5–5.5) 1.5 (0.5–4.4) p=NS 1.2 (0.5–1.4) p<0.05 2.6 (0.8–14) p=NS
Values expressed as means ± SD
Triacylglycerol and CRP values are presented as median (interquartile range) due to skewed distribution
DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure; TC, total cholesterol; TG, triacylglycerols
aDiabetes patients at baseline vs diabetes patients after 8 weeks of sulodexide
bBaseline diabetes patients vs baseline controls
cBaseline controls vs control participants after 8 weeks of sulodexide
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μm). In a subset of patients and controls (n=6 per group),
retinal glycocalyx dimensions were also determined both
before and after 8 weeks of sulodexide administration. The
retinal glycocalyx dimension was reduced in type 2
diabetes mellitus (5.38 μm [4.88–6.59] vs controls
8.89 μm [4.74–11.84], p<0.05 type 2 diabetes vs controls;
Fig. 4). Following administration of sulodexide for 8 weeks,
retinal glycocalyx thickness increased in participants with
type 2 diabetes mellitus (5.88 μm [5.33–6.26]; p=0.05 vs
baseline). In contrast to the effect on sublingual capillary
glycocalyx, sulodexide decreased retinal glycocalyx dimen-
sion in controls (to 4.87 [3.89–6.33] μm, p<0.05),
particularly in those with a relatively large glycocalyx
dimension at baseline (data not shown).
Transcapillary escape rate of albumin TERalb in the first
hour after infusion was increased in type 2 diabetes mellitus
patients (5.6±2.3% in patients vs 3.7±1.7% in controls, p<
0.05; Fig. 5). Following administration of sulodexide for
2 months, a trend towards normalisation of TERalb was
observed in those with type 2 diabetes mellitus (to 4.0±
2.3%, p=0.08) whereas in controls TERalb was unaffected
(to 3.3±1.6%).
Biochemistry Plasma hyaluronan levels were higher in type
2 diabetes mellitus patients compared with healthy controls
at baseline (137±29 vs 81±8 ng/ml, p<0.05; Fig. 6).
Plasma hyaluronidase levels (indicative of both endogenous
hyaluronan- and glycocalyx-degrading capacity) were also
increased in patients compared with controls (78±4 vs 67±
2 U/ml, p<0.05), which is in line with data from type 1
diabetes patients [10, 21]. Following sulodexide adminis-
tration in participants with type 2 diabetes mellitus, plasma
hyaluronidase activity decreased (from 78±4 to 72±2 U/l,
p<0.05) whereas hyaluronan levels were comparable (137±
29 vs 129±15 ng/ml; NS). In the controls, however,
hyaluronan increased (from 81±8 to 107±13 ng/ml,
p<0.05) as did plasma hyaluronidase activity (from 67±2
to 71±3 U/ml, p<0.05) following sulodexide administration.
Discussion
In the present study, we show that the endothelial
glycocalyx dimensions of both the sublingual and the
retinal microcirculation are decreased in patients with type
2 diabetes mellitus compared with healthy controls.
Following 8 weeks of sulodexide administration to estab-
lish enhanced precursor abundance for GAG synthesis,
glycocalyx dimensions improved in both the sublingual and
the retinal microvasculature. This improvement coincided
with a trend towards improvement of transcapillary albumin
escape rate and a reduction in hyaluronan catabolism. These
novel findings warrant further studies to evaluate whether
endothelial glycocalyx restoration may be of value as an
early marker predicting a risk reduction in vascular
complication rate in type 2 diabetes mellitus.
Following earlier reports in individuals with type 1
diabetes mellitus, we now demonstrate the presence of
glycocalyx perturbation in two different microvascular beds
in patients with type 2 diabetes mellitus [10]. The
significant reduction in glycocalyx dimensions in both
sublingual as well as retinal vessels in type 2 diabetes
underpins the systemic nature of glycocalyx perturbation.
The latter coincided with a significant increase in the
transcapillary escape rate of albumin indicative of increased
systemic permeability [21–25], lending further support to
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Fig. 2 Endothelial glycocalyx in control and type 2 diabetic
participants. a Compared with controls, median erythrocyte width
was significantly increased in participants with type 2 diabetes,
resulting in a significant movement of erythrocytes towards the vessel
wall; *p<0.05. Circles, controls; squares, type 2 diabetes group. b
Glycocalyx dimensions were reduced in the group with type 2
diabetes because of a significant increase in the median erythrocyte
width, while both control and diabetic participants had similar values
of the 90th percentiles of the erythrocyte column width (identifying
the position of the vessel wall), *p<0.05. Light circles, controls; dark
circles, type 2 diabetes group
2650 Diabetologia (2010) 53:2646–2655the concept of systemic glycocalyx perturbation in diabetes
mellitus. In this respect, experimental studies have implied
that the endothelial glycocalyx may be instrumental in
maintaining the endothelial barrier function under physio-
logical conditions [11]. Alterations in the proteoglycan/
glycosaminoglycan matrix structure of the endothelial
glycocalyx could adversely affect the charge-selective
repulsion of negatively charged proteins such as albumin,
resulting in increased transvascular leakage in both kidney
[26, 27] and the systemic vascular barrier in diabetes
mellitus [10]. However, systemic albumin clearance (TER-
alb) may not be the best method to evaluate changes in
systemic vascular permeability, particularly in diabetes
mellitus, as the impact of impaired reabsorption of albumin
in the proximal tubules in diabetes mellitus may outweigh
potential changes in systemic albumin leakage, as sug-
gested by Russo et al. [28].
Oral sulodexide supplementation was associated with a
significant improvement of both sublingual and retinal
endothelial glycocalyx dimensions as well as a trend
towards normalisation of the TERalb. Mechanistically, the
increased plasma hyaluronan levels and hyaluronidase
levels in type 2 diabetes at baseline may reflect increased
GAG catabolism in chronic hyperglycaemia [10], whereas
sulodexide reduced GAG metabolism as attested to by a
reduction of plasma hyaluronidase activity. Restoration of
GAG metabolism has been suggested to improve the barrier
function of the vasculature. Thus, Duling et al. previously
showed that enhanced abundance of precursors for endo-
thelial GAGs (particularly hyaluronan and unfractionated
heparin) led to restoration of the vasculo-protective capac-
ity of the endothelial glycocalyx [12, 29]. In the present
study, oral administration of sulodexide is expected to result
in enhanced precursor abundance, which may drive the
correction of the endothelial glycocalyx. As low-molecular-
weight heparins may also exert beneficial effects on
microalbuminuria and retinopathy in diabetes mellitus [30,
31], supplementation of other GAGs delivering comparable
molar equivalents of glucosamine, galactosamine and
glucuronic acid may share the beneficial properties of
sulodexide for endothelial glycocalyx.
The apparent conflicting results regarding the effect of
sulodexide on microalbuminuria deserve further discussion.
The trials reporting a beneficial effect of sulodexide
administration compared with placebo were all performed
in renin–angiotensin-inhibitor-naive normotensive type 2
 Fig. 3 The effect of sulodexide on endothelial glycocalyx in control
and diabetic participants. a Following sulodexide treatment, median
erythrocyte width decreased significantly in the type 2 diabetes group,
resulting in a significant restoration of the distance of erythrocytes
from the vessel wall; *p<0.05. White squares, diabetes group before
sulodexide exposure; black squares, diabetes group following sulo-
dexide treatment. b Following sulodexide treatment, median erythro-
cyte width was not significantly changed in controls, resulting in
similar distances of erythrocytes from the vessel. White circles,
control group before sulodexide exposure; black circles, diabetes
group following sulodexide treatment. c Glycocalyx dimensions at
baseline and after 8 weeks of treatment with sulodexide in controls
(n=10; con and Con_Sx, respectively) and diabetic participants
(n=10; DM2 and DM2_Sx, respectively) measured by SDF imaging
show sublingual glycocalyx dimensions were significantly reduced in
type 2 diabetes, and sulodexide treatment restored microvascular
glycocalyx dimensions to control values. Individual capillary glyco-
calyx dimensions were estimated from the transient widening of the
erythrocyte column. Data are presented as whisker plots with median
(interquartile range). *p<0.05
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Diabetologia (2010) 53:2646–2655 2651diabetes mellitus patients without overt vascular complica-
tions [32–34]. Recently, a beneficial effect of sulodexide
was also reported that was additive to those of angiotensin-
converting-enzyme inhibitors and/or angiotensin-receptor
blockers (ARBs) [35]. Notably, type 2 diabetes mellitus
patients in this trial were relatively young (mean age
55 years) without hypertension and with preserved renal
function, and hence had less prolonged hyperglycaemic
exposure. In contrast, two sulodexide trials performed in
type 2 diabetes mellitus patients aiming to show protective
effects of sulodexide additional to those of ARBs [36],
were terminated prematurely because of lack of an effect on
urinary albumin excretion [37]. However, patients included
in these trials were characterised by hypertension and
microalbuminuria, indicating glomerular endothelial dam-
age. Note that the microvascular endothelium may respond
differently upon therapeutic intervention compared with
glomerular endothelium (as determined by urinary albumin
excretion), reflecting different pathogenic pathways [38–
40]. In this respect, urinary albumin excretion in diabetes
mellitus has been attributed predominantly to proximal
tubular dysfunction [41, 42], which is independent from
changes in glycocalyx properties. Therefore, the lack of a
change in urinary albumin excretion in the aforementioned
trials does not preclude the finding of improved glycocalyx
properties in our normoalbuminuric patients. In addition,
the time scales may profoundly affect the observed results.
Thus, vascular barrier function restoration may follow at a
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Fig. 6 The effect of sulodexide on plasma glycosaminoglycans in
control and diabetic participants. a Circulating plasma hyaluronan
levels at baseline and after 8 weeks of sulodexide administration in
controls (n=10; con and Con_Sx, respectively) and diabetic partic-
ipants (n=10; DM2 and DM2_Sx, respectively). b Hyaluronidase
levels at baseline and after 8 weeks of sulodexide administration in
controls (n=10; con and Con_Sx, respectively) and diabetic partic-
ipants (n=10; DM2 and DM2_Sx, respectively), p<0.05 for compar-
ison of controls and controls following sulodexide treatment; p<0.01
for comparison of controls, controls following sulodexide treatment
and diabetes group before sulodexide treatment; p<0.05 for diabetes
group before and after sulodexide treatment. Data are presented as
whisker plots with median (interquartile range). *p<0.05, **p<0.01
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Fig. 5 The effect of sulodexide on vascular permeability in control
and diabetic participants. Percentage change in TERalb at baseline
and after 8 weeks of treatment with sulodexide in controls (n=10;
con and Con_Sx) and diabetic participants (n=10; DM2 and
DM2_Sx); p=NS for comparison of controls and controls following
sulodexide treatment. Microvascular permeability was determined by
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Fig. 4 The effect of sulodexide on retinal glycocalyx in control and
diabetic participants. Glycocalyx dimensions in controls at baseline
and after 8 weeks of treatment with sulodexide (n=6; con and
Con_Sx, respectively) and diabetic participants (n=6; DM2 and
DM2_Sx, respectively) measured by FAG/ICG. Individual glycocalyx
dimensions were estimated by subtracting the intravascular distribu-
tion of two different fluorescent tracers: indocyanine green from
fluorescein. Data are presented as whisker plots with median
(interquartile range). *p<0.05
2652 Diabetologia (2010) 53:2646–2655later stage when the endothelial glycocalyx is already
restored [12, 13]. To definitively answer the question
whether early intervention with sulodexide is able to
prevent the development of diabetes-associated microvas-
cular damage, a trial comparing sulodexide with placebo in
newly diagnosed normotensive/normoalbuminuric patients
with type 2 diabetes mellitus is warranted.
Mechanistically, measuring the impact of sulodexide
on glycocalyx dimension and properties in health and
disease is a challenge [15]. Endothelial glycocalyx
thickness depends on the rate of synthesis, the rate of
shedding as well as the circulating levels of GAG-
degrading enzymes, including hyaluronidase and hepara-
nase [43, 44]. Surprisingly, an increase in the sublingual
glycocalyx dimension with a concomitant decrease in
retinal glycocalyx was observed following sulodexide
administration in controls. These data imply that endothe-
lial responses are heterogeneous not only in patients with
type 2 diabetes compared with controls, but also in various
vascular beds [45]. Apparently, the endothelial glycocalyx
dimension is more closely regulated in the retina than the
sublingual microvessels [46]. The driving force behind
glycocalyx synthesis is most likely determined by enhanced
abundance of the precursors glucosamine, galactosamine
and glucuronic acid. Following intestinal degradation of
orally administered sulodexide, increased levels of GAG
precursors may contribute to the increased plasma levels of
hyaluronan and hyaluronidase in controls. In diabetes
mellitus, however, GAG degradation is increased [10, 21].
In these patients, decreased plasma hyaluronidase activity
may be attributed to the inhibition of enzymatic glycocalyx
degradation by the (sulodexide-mediated) increase in
substrate bioavailability [12]. In support, sulodexide has
been hypothesised to inhibit heparanase (and possibly
hyaluronidase) activity, both of which are involved in
GAG catabolism [47]. Therefore, in line with the pioneer-
ing study by Potter et al. [46], future in vitro endothelial
glycocalyx studies will have to focus on the effect of GAG
supplementation on the regulation of GAG-degrading
enzymes in different vascular endothelia (glomerular,
capillary and retina).
This study has several limitations. First, the dose of
sulodexide used was not validated by a formal dose-
finding study. Previous studies have indicated that a
treatment period as long as 6 months may be required to
establish the maximal effect [48]. This delayed mode of
action virtually precludes performing a meaningful dose-
finding study. Therefore, we selected the 200 mg sulodex-
ide dose based predominantly on previously published data
[35]. These data have shown improvement in the endothe-
lial barrier function using comparable concentrations of
sulodexide in vitro [16]. Note that further dose escalation
may also, at some point, be limited by the anticoagulant
effects of heparan sulphates, which could potentially lead to
bleeding complications. Second, our present proof-of-
concept study was rather small, with only type 2 diabetes
patients without cardiovascular and/or proteinuric disease
included. Whereas the findings are potentially interesting,
they need further confirmation in a larger cohort as well as
in type 2 diabetes patients with more severe stages of
vascular complications.
In conclusion, individuals with type 2 diabetes mellitus
are characterised by a clear perturbation of the endothelial
glycocalyx layer, which is thought to reflect increased
vascular vulnerability. Oral sulodexide administration
improves endothelial glycocalyx dimension to the same
extent in two different vascular beds (sublingual and retinal),
most likely because of enhanced precursor abundance for
GAG synthesis. Improvement of glycocalyx dimension
coincided with a trend toward normalised systemic vascular
permeability and GAG metabolism. Collectively, the present
findings imply that restoration of endothelial glycocalyx in
humans may be a promising target to attenuate vascular
dysfunction in type 2 diabetes mellitus. Further research is
required to evaluate which treatment modalities are most
likely to establish improvement in endothelial glycocalyx
dimension. More importantly, prospective studies should
address whether the concept holds true that endothelial
glycocalyx improvement predicts long-term cardiovascular
benefit in diabetes mellitus.
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